LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Raymond James 45th Annual Institutional Investors Conference in Orlando, Florida today, Monday, March 4, 2024 at 3:25 p.m. Eastern Time.
A live webcast of RadNet's presentation can be accessed through the following link, https://wsw.com/webcast/rj129/rdnt/1616960 and is available for replay viewing. The Raymond James 45th Annual Institutional Investors Conference will take place at the JW Marriott Grande Lakes, Orlando.
Details for RadNet's Presentation: | |
Date: Time: Location: | Monday, March 4th, 2024 3:25 p.m. Eastern Time JW Marriott Grande Lakes, Orlando, FL |
About RadNet, Inc.
RadNet, Inc., is the leading national provider of free-standing, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida, and Arizona. Together with affiliated radiologists, including full-time and per diem employees and technologists, RadNet has over 9,700 employees.
For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2800
Last Trade: | US$81.82 |
Daily Change: | -0.34 -0.41 |
Daily Volume: | 63,092 |
Market Cap: | US$6.050B |
November 11, 2024 November 10, 2024 November 07, 2024 September 17, 2024 September 12, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB